Reporters learned that the World Health Organization (WHO) is developing new guidelines for the treatment of adult obesity based on GLP-1 therapy, which is scheduled to be officially released in September 2025. The guidelines are developed by an independent Guideline Development Group (GDG), whose members include experts in the field of obesity, epidemiologists, clinical management experts, pharmacologists, health economists, public health program experts and policy makers to ensure that the guidelines meet the strict standards of the World Health Organization. It is reported that the purpose of the guidelines is to clarify the clinical indications, applications and planning considerations of GLP 1 RAs. The guidelines are expected to be the first time that the World Health Organization has officially recommended the use of weight loss drugs to treat adult obesity. The move marks a major policy shift for the global health agency in addressing the growing obesity crisis.